CRON vs. XENE, MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, and ARWR
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.
Cronos Group vs.
Cronos Group (NASDAQ:CRON) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Cronos Group currently has a consensus price target of $3.00, suggesting a potential upside of 52.28%. Xenon Pharmaceuticals has a consensus price target of $57.38, suggesting a potential upside of 44.41%. Given Cronos Group's higher probable upside, research analysts plainly believe Cronos Group is more favorable than Xenon Pharmaceuticals.
Cronos Group has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 6.9% of Cronos Group shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cronos Group has higher revenue and earnings than Xenon Pharmaceuticals. Cronos Group is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cronos Group received 44 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. However, 70.00% of users gave Xenon Pharmaceuticals an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Xenon Pharmaceuticals' return on equity.
In the previous week, Xenon Pharmaceuticals had 8 more articles in the media than Cronos Group. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 0 mentions for Cronos Group. Xenon Pharmaceuticals' average media sentiment score of 0.67 beat Cronos Group's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.
Summary
Xenon Pharmaceuticals beats Cronos Group on 11 of the 19 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
This page (NASDAQ:CRON) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CRON Stock Alerts